uniQure (QURE) News Today $15.56 +1.15 (+7.94%) As of 12:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QURE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period uniQure: Price And Value Have Caught UpJune 17, 2025 | seekingalpha.comuniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy OfficerJune 11, 2025 | globenewswire.comuniQure Provides Regulatory Update on AMT-130 for Huntington's DiseaseJune 2, 2025 | globenewswire.comuniQure N.V. (QURE) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comuniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company ProgressMay 9, 2025 | globenewswire.comuniQure to Announce First Quarter 2025 Financial ResultsMay 5, 2025 | globenewswire.comuniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A HoldApril 21, 2025 | seekingalpha.comuniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130April 21, 2025 | seekingalpha.comuniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's DiseaseApril 17, 2025 | globenewswire.comuniQure Announces 2024 Financial Results and Highlights Recent Company ProgressFebruary 27, 2025 | globenewswire.comuniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four YearsFebruary 7, 2025 | benzinga.comCSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia BFebruary 7, 2025 | prnewswire.comuniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseFebruary 3, 2025 | globenewswire.comuniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALSJanuary 30, 2025 | globenewswire.comuniQure Announces Pricing of its Public OfferingJanuary 8, 2025 | globenewswire.comuniQure Announces Proposed Public OfferingJanuary 7, 2025 | globenewswire.comUp 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?December 15, 2024 | fool.comuniQure's AMT-130: A Bold Step For Huntington's, But Not Without HurdlesDecember 10, 2024 | seekingalpha.comuniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's DiseaseDecember 10, 2024 | globenewswire.comuniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe EpilepsyNovember 21, 2024 | globenewswire.comuniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNovember 5, 2024 | globenewswire.comuniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALSOctober 15, 2024 | globenewswire.comuniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry DiseaseSeptember 23, 2024 | globenewswire.comuniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseAugust 15, 2024 | globenewswire.comQURE Stock Earnings: uniQure Beats EPS, Beats Revenue for Q2 2024August 1, 2024 | investorplace.comuniQure Announces Second Quarter 2024 Financial Results and Provides Company UpdateAugust 1, 2024 | globenewswire.comuniQure Announces Closing of Sale of Manufacturing Facility to GenezenJuly 23, 2024 | globenewswire.comWhy Is uniQure (QURE) Stock Up 51% Today?July 9, 2024 | investorplace.comuniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's DiseaseJuly 9, 2024 | globenewswire.comGenezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MAJuly 1, 2024 | prnewswire.comuniQure Announces Sale of Commercial Manufacturing Facility to GenezenJuly 1, 2024 | globenewswire.comuniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's DiseaseJune 3, 2024 | globenewswire.comQURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024May 7, 2024 | investorplace.comuniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 7, 2024 | globenewswire.comuniQure Announces 2023 Financial Results and Highlights Recent Company ProgressFebruary 28, 2024 | globenewswire.comuniQure (Nasdaq:QURE) HeadlineTrading was temporarily halted for "QURE" at 07:10 AM with a stated reason of "News pending."...October 5, 2023 | marketbeat.comuniQure: The AMT-130 ReadoutJuly 17, 2023 | seekingalpha.comMarket Is Still Not Pricing In The FDA And EU EMA Approvals For uniQureMay 22, 2023 | seekingalpha.comuniQure: Financials And Pipeline Signal A Promising Outlook For InvestorsMay 20, 2023 | seekingalpha.comuniQure (NASDAQ:QURE) Director Sells $157,356.00 in StockuniQure (NASDAQ:QURE) Director Sells $157,356.00 in Stock...December 4, 2022 | marketbeat.comuniQure (NASDAQ:QURE) Price Target Increased to $57.00 by Analysts at The Goldman Sachs GroupuniQure (NASDAQ:QURE) Price Target Increased to $57.00 by Analysts at The Goldman Sachs Group...November 24, 2022 | marketbeat.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease - GlobeNewswireFebruary 7, 2022 | globenewswire.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s DiseaseFebruary 7, 2022 | finance.yahoo.comWith CRISPR gene editing, unique treatments begin to take off for rare diseases - The Washington PostFebruary 5, 2022 | washingtonpost.comGlobal Gene Therapy for Blood Disorders Market worth US$ 5.79 Billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo FinanceFebruary 4, 2022 | finance.yahoo.comEAHAD 2022 - Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Sever or Moderately Severe Hemophilia B - Marketscreener.comFebruary 4, 2022 | marketscreener.comM5 unique date ideas in NW Arkansas - AxiosFebruary 4, 2022 | axios.comAAmazon has a unique inflation problem - ReutersFebruary 4, 2022 | reuters.comBears hope Justin Fields ‘skyrockets’ — but his rookie struggles weren’t unique - Chicago Sun-TimesFebruary 3, 2022 | chicago.suntimes.comCTurkey's Recep Tayyip Erdogan is the latest leader to visit Ukraine - The Washington PostFebruary 3, 2022 | washingtonpost.com Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Email Address QURE Media Mentions By Week QURE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QURE News Sentiment▼1.890.96▲Average Medical News Sentiment QURE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QURE Articles This Week▼10▲QURE Articles Average Week Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMVT News AAPG News CRNX News KYMR News MOR News HCM News RARE News ALVO News AMRX News MIRM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QURE) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
